세계의 롱 리드 시퀀싱 시장 : 용도별, 수법별, 제품별, 최종 사용자별-기회 분석 및 산업 예측(2023-2032년)

Long Read Sequencing Market By Application, By Technique (Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Synthetic Long Read Sequencing), By Product, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,891,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,221,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

롱리드 시퀀싱 시장은 2022년에 7억 2,443만 달러로 평가되었고, 2023년부터 2032년까지 21.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망이며, 2032년에는 51억 6,341만 달러에 이를 것으로 추정됩니다. 롱 리드 시퀀싱은 기존 기술에 비해 더 긴 DNA 스트레치를 읽는 게놈 기술입니다. 1분자 시퀀싱와 같은 혁신적인 기술을 채택하여 수천에서 수백만 염기쌍에 이르는 DNA 서열을 생성합니다. Pacific Biosciences와 Oxford Nanopore Technologies와 같은 플랫폼은 나노포어 시퀀싱와 같은 기술을 활용하여 리드 길이를 연장하고 있습니다. 롱 리드 시퀀싱은 복잡한 게놈 영역, 반복 서열, 구조 돌연변이의 종합적인 분석을 용이하게 합니다. 그 용도로는 de novo 게놈 어셈블리, 복잡한 게놈 구조 해명, 유전성 질환 이해, 미생물 다양성 탐구 등이 있습니다. 전반적으로, 롱 리드 시퀀싱은 상세하고 정확한 게놈 정보를 제공함으로써 게놈 연구에 혁명을 가져옵니다.

유전성 질환과 암 유병률의 상승은 롱 리드 시퀀싱 기술에 대한 수요 증가의 큰 원동력이 되고 있습니다. 유전성 질환과 암은 돌연변이, 구조 변이, 게놈 재배열 등 여러 유전적 요인의 영향을 받는 본질적으로 복잡한 질환입니다. 롱 리드 시퀀싱은 전체 게놈을 종합적으로 분석할 수 있는 능력을 제공하여 연구자와 임상의가 이러한 질병과 관련된 희귀하고 신규한 유전자 변이를 보다 정확하게 확인할 수 있게 합니다. 예를 들어 세계보건기구(WHO)는 세계 매년 약 40만 명의 유아가 암을 앓고 있는 것으로 추정하고 있으며, 암의 유전적 기반을 보다 잘 이해하고 표적요법을 개발 하기위한 고급 게놈 기술이 긴급히 필요하다는 것을 강조합니다. 질병의 근본적인 유전적 메커니즘에 대한 인사이트를 제공함으로써 Long Lead Sequence는 Precision Medicin의 이니셔티브를 추진하고 유전 질환과 암 환자의 임상 결과를 개선하는 데 중요한 역할을 합니다.

게다가, 시퀀싱 비용이 낮고 다양한 영역에서 유전체학의 중요성에 대한 인식이 높아지고 있는 가운데, 종합적인 게놈 인사이트에 대한 수요가 증가하고 있습니다. 롱 리드 시퀀싱은 게놈의 구조와 기능을 더 깊이 이해하기 때문에 연구자는 복잡한 유전적 변이를 밝히고 질병, 형질 및 진화 과정의 유전적 기초를 더 깊이 이해할 수 있습니다. 이와 같이, 유전성 질환이나 암 질환 증가, 질환 진단에 있어서의 롱 리드 시퀀싱의 폭넓은 응용은 잠재적으로 시장의 성장을 저해하고 있습니다.

그러나 롱 리드 시퀀싱 부문에서는 숙련된 전문가 부족이 시장 성장을 방해할 것으로 예상됩니다. 롱 리드 시퀀싱 플랫폼에서 데이터를 조작하고 해석하려면 분자 생물학, 생물 정보학 및 유전체학의 전문 지식이 필요합니다. 충분한 훈련을 받은 인력이 부족하여 롱 리드 시퀀싱술의 채용과 이용이 제한되어 연구, 임상 진단 및 산업 용도 도입이 지연될 수 있습니다.

롱 리드 시퀀싱 시장은 용도, 기술, 제품, 최종 사용자, 지역별로 구분됩니다. 용도별로는 연구 용도와 임상 용도로 이분됩니다. 기술별로는 1분자 실시간 시퀀싱(SMRT), 나노포어 시퀀싱, 합성 롱 리드 시퀀싱로 분류됩니다. 제품별로는 기기, 소모품, 서비스로 구분됩니다. 장치 부문은 또한 시스템과 소프트웨어로 분류됩니다. 최종 사용자별로는 학술 및 정부연구기관, 제약 및 바이오테크놀러지 기업, 병원 및 클리닉 등으로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 인도, 호주, 한국, 기타 아시아태평양), LAMEA(브라질, 남아프리카, 사우디아라비아, 기타 LAMEA)에서 분석됩니다.

이해관계자를 위한 주요 이점

본 보고서에서는 2022년부터 2032년까지 롱 리드 시퀀싱 시장 분석 시장 부문, 현재의 동향, 추정 및 동향, 역학을 정량적으로 분석하여 롱 리드 시퀀싱 시장의 유력한 기회를 특정합니다.

시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회에 관련된 정보와 함께 시장 조사를 기재하고 있습니다.

Porter's Five Forces 분석은 이해관계자들이 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자 및 공급업체의 잠재력을 보여줍니다.

롱 리드 시퀀싱 시장의 세분화를 상세하게 분석함으로써 시장 기회를 파악할 수 있습니다.

각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.

시장 진출기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 진출기업의 현재 포지션을 명확하게 이해할 수 있습니다.

이 보고서에는 지역 및 세계의 롱 리드 시퀀싱 시장 동향, 주요 기업, 시장 부문, 용도 부문 및 시장 성장 전략의 분석이 포함되어 있습니다.

이 보고서에서 가능한 맞춤설정(추가 비용 및 일정 필요)

• 규제 가이드라인
• 고객의 관심에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• 주요 진출기업의 상세(소재지, 연락처, 공급업체 및 벤더 네트워크 등을 포함한 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 정밀의료에 대한 수요 증가
    • 제휴 및 공동 연구수 증가
    • 주요 기업에 의한 창약에 대한 대처 증가
  • 억제요인
    • 높은 초기 투자 및 비용
  • 기회
    • 기술 진보 증가

제4장 롱 리드 시퀀싱 시장 : 용도별

• 개요
• 연구 용도
• 임상 용도

제5장 롱 리드 시퀀싱 시장 : 기술별

• 개요
• 단일 분자 실시간(SMRT) 시퀀싱
• 나노포어 시퀀싱
• 합성 롱 리드 시퀀싱

제6장 롱 리드 시퀀싱 시장 : 제품별

• 개요
• 장치
  • 롱 리드 시퀀싱 장치 시장 : 유형별
• 소모품
• 서비스

제7장 롱 리드 시퀀싱 시장 : 최종 사용자별

• 개요
• 학술 및 정부연구기관
• 제약 및 바이오테크놀러지 기업
• 병원 및 클리닉
• 기타

제8장 롱리드 시퀀싱 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카
  • 기타

제9장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제10장 기업 프로파일

• Agilent Technologies, Inc.
• BaseClear BV
• Cantata Bio
• Element Biosciences
• FG Technologies
• GrandOmics
• Illumina, Inc.
• MicrobesNG
• Novogene co., ltd.
• Oxford Nanopore Technologies plc.
• PacBio
• St Vincents Hospital Melbourne
• TAKARA HOLDINGS INC.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• BGI Genomics
• CD Genomics

AJY

영문 목차

영문목차

The long read sequencing market was valued at $724.43 million in 2022 and is estimated to reach $5,163.41 million by 2032, exhibiting a CAGR of 21.7% from 2023 to 2032. Long read sequencing is a genomic technique that reads longer stretches of DNA compared to traditional methods. It employs innovative technologies like single-molecule sequencing to generate DNA sequences spanning thousands to millions of base pairs. Platforms such as Pacific Biosciences and Oxford Nanopore Technologies utilize techniques such as nanopore sequencing to achieve extended read lengths. Long read sequencing facilitates comprehensive analysis of complex genomic regions, repetitive sequences, and structural variations. Its applications include de novo genome assembly, resolving complex genomic structures, understanding genetic diseases, and exploring microbial diversity. Overall, long read sequencing revolutionizes genomic research by providing detailed and accurate genomic information.

The rise in the prevalence of genetic disorders and cancer is indeed a significant driver for the increased demand for long read sequencing technologies. Genetic disorders and cancer are inherently complex diseases influenced by multiple genetic factors, including mutations, structural variations, and genomic rearrangements. Long read sequencing offers the ability to comprehensively analyze the entire genome, enabling researchers and clinicians to identify rare and novel genetic variants associated with these diseases more accurately. For instance, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year worldwide, emphasizing the urgent need for advanced genomic technologies to better understand the genetic basis of cancer and develop targeted therapies. By providing insights into the underlying genetic mechanisms of disease, long read sequencing plays a crucial role in advancing precision medicine initiatives and improving clinical outcomes for patients with genetic disorders and cancer.

In addition, with the decreasing cost of sequencing and increasing awareness of the importance of genomics in various domains, there's a growing demand for comprehensive genomic insights. Long read sequencing provides a deeper understanding of genomic structure and function, allowing researchers to uncover complex genetic variations and better understand the genetic basis of diseases, traits, and evolutionary processes. Thus, the rise in genetic and cancer disorders and the wide application of long read sequencing in the disease diagnosis is potentially diving the market growth.

However, the lack of skilled professionals in the field of long read sequencing is expected to hinder market growth. Operating and interpreting data from long read sequencing platforms require specialized expertise in molecular biology, bioinformatics, and genomics. The shortage of adequately trained personnel may limit the adoption and utilization of long read sequencing technologies, delaying their implementation in research, clinical diagnostics, and industrial applications.

The long read sequencing market is segmented on the basis of application, technique, product, end user, and region. By application, it is bifurcated into research application and clinical application. By technique, the market is categorized into single-molecule real-time sequencing (SMRT), nanopore sequencing and synthetic long read sequencing. On the basis of product, it is segmented into instruments, consumables, and services. The instrument segment is further classified into system and software. By end user, it is segregated into academic and government research institutes, pharmaceutical and biotechnological companies, hospitals and clinics, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global long read sequencing market are Agilent Technologies, Inc. BaseClear BV, Cantata Bio, FG Technologies, Grandomics, MicrobesNG, Novogene co., ltd., Oxford Nanopore Technologies, Pacific Biosciences Inc., CD Genomics, Danaher Corporation, BGI Genomics, St Vincent's Hospital Australia, Takara Holdings Inc., Thermo Fisher Scientific, Inc., Element Biosciences, and Illumina, Inc. Key players operating in the market have adopted product launch, acquisition, partnership and collaboration as their key strategy to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the long read sequencing market analysis from 2022 to 2032 to identify the prevailing long read sequencing market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the long read sequencing market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global long read sequencing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Application

• Research Applications
• Clinical Applications

By Technique

• Nanopore Sequencing
• Synthetic Long Read Sequencing
• Single-Molecule Real-Time (SMRT) Sequencing

By Product

• Instruments
  • Type
  • System
  • Software
• Consumables
• Services

By End User

• Academic and Government Research Institutes
• Pharmaceutical and Biotech Companies
• Hospitals and Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Cantata Bio
• Illumina, Inc.
• Danaher Corporation
• Element Biosciences
• FG Technologies
• MicrobesNG
• Oxford Nanopore Technologies plc.
• CD Genomics
• BGI Genomics
• St Vincents Hospital Melbourne
• Agilent Technologies, Inc.
• TAKARA HOLDINGS INC.
• BaseClear B.V.
• GrandOmics
• Novogene co., ltd.
• PacBio
• Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in demand for precision medicine
    • 3.4.1.2. Rise in number of partnership and collaboration
    • 3.4.1.3. The growing initiatives taken by the key players for drug discovery
  • 3.4.2. Restraints
    • 3.4.2.1. High Initial Investment and Cost
  • 3.4.3. Opportunities
    • 3.4.3.1. Rise in technological advancements

CHAPTER 4: LONG READ SEQUENCING MARKET, BY APPLICATION

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Research Applications
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Clinical Applications
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: LONG READ SEQUENCING MARKET, BY TECHNIQUE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Single-Molecule Real-Time (SMRT) Sequencing
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Nanopore Sequencing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Synthetic Long Read Sequencing
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: LONG READ SEQUENCING MARKET, BY PRODUCT

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Instruments
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
  • 6.2.4. Instruments Long Read Sequencing Market by Type
• 6.3. Consumables
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Services
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: LONG READ SEQUENCING MARKET, BY END USER

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Academic and Government Research Institutes
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Pharmaceutical and Biotech Companies
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Hospitals and Clinics
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country
• 7.5. Others
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by region
  • 7.5.3. Market share analysis by country

CHAPTER 8: LONG READ SEQUENCING MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by Application
  • 8.2.3. Market size and forecast, by Technique
  • 8.2.4. Market size and forecast, by Product
  • 8.2.5. Market size and forecast, by End User
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Market size and forecast, by Application
    • 8.2.6.1.2. Market size and forecast, by Technique
    • 8.2.6.1.3. Market size and forecast, by Product
    • 8.2.6.1.4. Market size and forecast, by End User
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Market size and forecast, by Application
    • 8.2.6.2.2. Market size and forecast, by Technique
    • 8.2.6.2.3. Market size and forecast, by Product
    • 8.2.6.2.4. Market size and forecast, by End User
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Market size and forecast, by Application
    • 8.2.6.3.2. Market size and forecast, by Technique
    • 8.2.6.3.3. Market size and forecast, by Product
    • 8.2.6.3.4. Market size and forecast, by End User
• 8.3. Europe
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by Application
  • 8.3.3. Market size and forecast, by Technique
  • 8.3.4. Market size and forecast, by Product
  • 8.3.5. Market size and forecast, by End User
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Market size and forecast, by Application
    • 8.3.6.1.2. Market size and forecast, by Technique
    • 8.3.6.1.3. Market size and forecast, by Product
    • 8.3.6.1.4. Market size and forecast, by End User
    • 8.3.6.2. France
    • 8.3.6.2.1. Market size and forecast, by Application
    • 8.3.6.2.2. Market size and forecast, by Technique
    • 8.3.6.2.3. Market size and forecast, by Product
    • 8.3.6.2.4. Market size and forecast, by End User
    • 8.3.6.3. UK
    • 8.3.6.3.1. Market size and forecast, by Application
    • 8.3.6.3.2. Market size and forecast, by Technique
    • 8.3.6.3.3. Market size and forecast, by Product
    • 8.3.6.3.4. Market size and forecast, by End User
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Market size and forecast, by Application
    • 8.3.6.4.2. Market size and forecast, by Technique
    • 8.3.6.4.3. Market size and forecast, by Product
    • 8.3.6.4.4. Market size and forecast, by End User
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Market size and forecast, by Application
    • 8.3.6.5.2. Market size and forecast, by Technique
    • 8.3.6.5.3. Market size and forecast, by Product
    • 8.3.6.5.4. Market size and forecast, by End User
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Market size and forecast, by Application
    • 8.3.6.6.2. Market size and forecast, by Technique
    • 8.3.6.6.3. Market size and forecast, by Product
    • 8.3.6.6.4. Market size and forecast, by End User
• 8.4. Asia-Pacific
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by Application
  • 8.4.3. Market size and forecast, by Technique
  • 8.4.4. Market size and forecast, by Product
  • 8.4.5. Market size and forecast, by End User
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Market size and forecast, by Application
    • 8.4.6.1.2. Market size and forecast, by Technique
    • 8.4.6.1.3. Market size and forecast, by Product
    • 8.4.6.1.4. Market size and forecast, by End User
    • 8.4.6.2. China
    • 8.4.6.2.1. Market size and forecast, by Application
    • 8.4.6.2.2. Market size and forecast, by Technique
    • 8.4.6.2.3. Market size and forecast, by Product
    • 8.4.6.2.4. Market size and forecast, by End User
    • 8.4.6.3. India
    • 8.4.6.3.1. Market size and forecast, by Application
    • 8.4.6.3.2. Market size and forecast, by Technique
    • 8.4.6.3.3. Market size and forecast, by Product
    • 8.4.6.3.4. Market size and forecast, by End User
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Market size and forecast, by Application
    • 8.4.6.4.2. Market size and forecast, by Technique
    • 8.4.6.4.3. Market size and forecast, by Product
    • 8.4.6.4.4. Market size and forecast, by End User
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Market size and forecast, by Application
    • 8.4.6.5.2. Market size and forecast, by Technique
    • 8.4.6.5.3. Market size and forecast, by Product
    • 8.4.6.5.4. Market size and forecast, by End User
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Market size and forecast, by Application
    • 8.4.6.6.2. Market size and forecast, by Technique
    • 8.4.6.6.3. Market size and forecast, by Product
    • 8.4.6.6.4. Market size and forecast, by End User
• 8.5. LAMEA
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by Application
  • 8.5.3. Market size and forecast, by Technique
  • 8.5.4. Market size and forecast, by Product
  • 8.5.5. Market size and forecast, by End User
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Market size and forecast, by Application
    • 8.5.6.1.2. Market size and forecast, by Technique
    • 8.5.6.1.3. Market size and forecast, by Product
    • 8.5.6.1.4. Market size and forecast, by End User
    • 8.5.6.2. Saudi Arabia
    • 8.5.6.2.1. Market size and forecast, by Application
    • 8.5.6.2.2. Market size and forecast, by Technique
    • 8.5.6.2.3. Market size and forecast, by Product
    • 8.5.6.2.4. Market size and forecast, by End User
    • 8.5.6.3. South Africa
    • 8.5.6.3.1. Market size and forecast, by Application
    • 8.5.6.3.2. Market size and forecast, by Technique
    • 8.5.6.3.3. Market size and forecast, by Product
    • 8.5.6.3.4. Market size and forecast, by End User
    • 8.5.6.4. Rest of LAMEA
    • 8.5.6.4.1. Market size and forecast, by Application
    • 8.5.6.4.2. Market size and forecast, by Technique
    • 8.5.6.4.3. Market size and forecast, by Product
    • 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product mapping of top 10 player
• 9.4. Competitive dashboard
• 9.5. Competitive heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Agilent Technologies, Inc.
  • 10.1.1. Company overview
  • 10.1.2. Key executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
• 10.2. BaseClear B.V.
  • 10.2.1. Company overview
  • 10.2.2. Key executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
• 10.3. Cantata Bio
  • 10.3.1. Company overview
  • 10.3.2. Key executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Key strategic moves and developments
• 10.4. Element Biosciences
  • 10.4.1. Company overview
  • 10.4.2. Key executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Key strategic moves and developments
• 10.5. FG Technologies
  • 10.5.1. Company overview
  • 10.5.2. Key executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
• 10.6. GrandOmics
  • 10.6.1. Company overview
  • 10.6.2. Key executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Key strategic moves and developments
• 10.7. Illumina, Inc.
  • 10.7.1. Company overview
  • 10.7.2. Key executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
  • 10.7.6. Business performance
  • 10.7.7. Key strategic moves and developments
• 10.8. MicrobesNG
  • 10.8.1. Company overview
  • 10.8.2. Key executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
• 10.9. Novogene co., ltd.
  • 10.9.1. Company overview
  • 10.9.2. Key executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Key strategic moves and developments
• 10.10. Oxford Nanopore Technologies plc.
  • 10.10.1. Company overview
  • 10.10.2. Key executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Key strategic moves and developments
• 10.11. PacBio
  • 10.11.1. Company overview
  • 10.11.2. Key executives
  • 10.11.3. Company snapshot
  • 10.11.4. Operating business segments
  • 10.11.5. Product portfolio
  • 10.11.6. Business performance
  • 10.11.7. Key strategic moves and developments
• 10.12. St Vincents Hospital Melbourne
  • 10.12.1. Company overview
  • 10.12.2. Key executives
  • 10.12.3. Company snapshot
  • 10.12.4. Operating business segments
  • 10.12.5. Product portfolio
• 10.13. TAKARA HOLDINGS INC.
  • 10.13.1. Company overview
  • 10.13.2. Key executives
  • 10.13.3. Company snapshot
  • 10.13.4. Operating business segments
  • 10.13.5. Product portfolio
  • 10.13.6. Business performance
• 10.14. Thermo Fisher Scientific Inc.
  • 10.14.1. Company overview
  • 10.14.2. Key executives
  • 10.14.3. Company snapshot
  • 10.14.4. Operating business segments
  • 10.14.5. Product portfolio
  • 10.14.6. Business performance
• 10.15. Danaher Corporation
  • 10.15.1. Company overview
  • 10.15.2. Key executives
  • 10.15.3. Company snapshot
  • 10.15.4. Operating business segments
  • 10.15.5. Product portfolio
  • 10.15.6. Business performance
• 10.16. BGI Genomics
  • 10.16.1. Company overview
  • 10.16.2. Key executives
  • 10.16.3. Company snapshot
  • 10.16.4. Operating business segments
  • 10.16.5. Product portfolio
• 10.17. CD Genomics
  • 10.17.1. Company overview
  • 10.17.2. Key executives
  • 10.17.3. Company snapshot
  • 10.17.4. Operating business segments
  • 10.17.5. Product portfolio

관련자료